Cada médico generalista, cada
ginecólogo, cada médico debería conocer:
·
El diagnóstico
clínico de la deficiencia androgénica en la mujer.
·
El diagnóstico biológico simplificado
y no costoso de la deficiencia androgénica en la mujer.
·
La eficacia del tratamiento poco costoso del
tratamiento de las deficiencias androgénicas en la mujer.
El estudio del doctor Georges Debled puso de relieve
el concepto de “enfermedad menopausia”
-
Se asignaron numerosos desordenes de la menopausia
incorrectamente al defecto de secreción de estradiol y
progesterona.
Los médicos en
general.consideran este concepto contaminado aún como un
dogma.
-
El Gobierno de los Estados Unidos no permite la
importación y la prescripción de mesterolona. (La razón
que es que la administración responsable no ve la
utilidad).
-
La industria farmacéutica reserva la utilización de la
mesterolona solamente para los hombres y la prohibición
en la mujer.
-
El estudio del doctor Georges Debled sobre la menopausia
comenzó en
1996.
Se continuó después consolidada por las
conclusiones del WHI
(Women’s
Health Initiative)
en
2002. JAMA. 2002 Jul
17;288(3):321-33(5).
-
Este estudio confidencial fue realizable porque la
mesterolona puede obtenerse y prescribirse en Europa.
-
Después de la conclusión de la Women' s Health
Iniciativa en 2002 (5) y la condena por el Tribunal
Supremo de los Estados Unidos (17), el doctor Georges
Debled publica por primera vez sus conclusiones sobre el
tratamiento de las deficiencias androgenicas en la mujer
por la mesterolona. Se trata de una solución
válida para compensar las deficiencias en andrógenos
antes y después de la menopausia. Este estudio no se
publicó nunca en una revista científica ni en una
revista general. No se presentó en ninguna conferencia y
en ningún congreso. (18).
·
Se trata de un concepto completamente nuevo (18).
Investigaciones futuras
Estudios complementarios a
grande escala serán necesarios para especificar los
contornos del tratamiento por la mesterolona de las
deficiencias androgénicas en la mujer. Estos estudios a
amplia escala deberán tener en cuenta la biología de los andrógenos en la mujer.
Deberían suscitar el
interés de los Gobiernos y de la industria farmacéutica
para luchar contra las
enfermedades del envejecimiento.
Bibliografía
1. Hormones.
E-E Baulieu and Paul A.Kelly. Hermann
publishers1990)
2. Twenty-four
hours mean plasma testosterone concentration
decline in non premenopausal women. Zumoff
B, Strain GW,Miller LK, Rosner W. J Clin
Endocrinol Metab, 1995, 80:1429-1430
3. Consequences
of oral contraceptive troubles with decrease
of androgen ovarian
synthesis. Harrison’s
Principes de medicine interne – 331 :
Maladies de l’ovaire et de l’appareil
génital féminin: p. 1832-1833, 1988.
3.1. Effects
of oral contraceptives on breast epithelial
proliferation. Isaksson
E, von Schoultz E, Odlind V, Soderqvist G,
Csemiczky G, Carlstrom K, Skoog L, von
Schoultz B. Department
of Oncology, Radiumhemmet, Karolinska
Hospital, Stockholm, Sweden Breast
Cancer Res Treat2001 Jan;
65(2):163-169
3.2 Oral
contraceptive use as a risk factor for
premenopausal breast cancer: a
meta-analysis.
Kahlenborn C, Modugno
F, Potter
DM, Severs
WB. Mayo
Clin Proc. 2006
Oct;81(10):1290-302.
3.3. Effect of Depo-Medroxyprogesterone
Acetate on Breast Cancer Risk among Women 20
to 44 Years of Age. Christopher
I. Li, Elisabeth
F. Beaber, Mei
Tzu Chen Tang,Peggy
L. Porter, Janet
R.Daling,
Kathleen
E. Malone. Cancer
Res; 72(8); 2028–35.2012
4. Impact
of Oral Contraceptives on Sex
Hormone-Binding Globulin and Androgen
Levels: A Retrospective Study in Women with
Sexual Dysfunction.Panzer et al. The
Journal of Sexual Medicine, January
2006;3:p.104-113
5. Risks
and benefits of estrogen plus progestin in
healthy postmenopausal women: principal
results From the Women's Health Initiative
randomized controlled trial. Rossouw
JE, Anderson GL, Prentice RL, LaCroix AZ,
Kooperberg C, Stefanick ML, Jackson RD,
Beresford SA, Howard BV, Johnson KC, Kotchen
JM, Ockene J; Writing Group for the Women's
Health Initiative Investigators. JAMA.
2002 Jul 17;288(3):321-33.
6. Promotional
tone in reviews of menopausal hormone
therapy after the Women's Health Initiative:
an analysis of published articles.Fugh-Berman
A, McDonald CP, Bell AM, Bethards EC,
Scialli AR.Department of Physiology and
Biophysics, Georgetown University Medical
Center, Washington, DC, USA.PLoS Med. 2011
Mar;8(3):e1000425. Epub 2011 Mar 15.
7.
Androgens and osteocalcin during the
menstrual cycle.
Massafra C, De Felice C, Agnusdei DP, Gioia
D, Bagnoli F. Department of Obstetrics and
Gynecology, University of Siena, Italy. J
Clin Endocrinol Metab. 1999 Mar;84(3):971-4
8.Testosterone measured by 10
immunoassays and by isotope-dilution gas
chromatography-mass spectrometry in sera
from 116 men,women, and children. Taieb
J, Mathian B, Millot F, Patricot MC, Mathieu
E, Queyrel N, Lacroix I, Somma-Delpero C,
Boudou P. Hormonology Laboratory, A. Béclère
Hospital, 92141 Clamart, France. Clinical
Chemistry 49, 1381-1395, 2003.
9. Androgen
levels in adult females: changes with age,
menopause, and oophorectorny. Davison
SL, Bell R, Donath S, Montalto JG, Davis SR.
J Clin Endocrinol Metab, 2005, 90:3847-53.
10. Androgen
glucuronides, instead of testosterone, as
the new markers of androgenic activity in
women.Labrie F, Bélanger A, Bélanger R
Bérubé R, Martel C, Cusan L, Gomez J, Candas
B, Castiel I, Chaussade V, Deloche C,
Leclaire J.. J Steroid Biochem Mol Biol,
2006, 99:182-188.
11. Wide
distribution of the serum
dehydroepiandrosterone and sex steroid
levels in postmenopausal women: role of the
ovary? Labrie
F, Martel C, Balser J. Endoceutics
Inc, Quebec City, Quebec, Canada. Menopause.2011
Jan: 18 (1):30-43.
12. Low
testosterone levels predict all-cause
mortality and cardiovascular events in
women: a prospective cohort study in German
primary care patients. Sievers
C, Klotsche J, Pieper L, Schneider HJ, März
W, Wittchen HU, Stalla GK, Mantzoros
C.Department of Endocrinology, Max Planck
Institute of Psychiatry, Kraepelinstrasse
2-10, Munich, Germany. Eur J Endocrinol.
2010 Oct;163(4):699-708. Epub 2010 Aug 4.
13. Higher
serum free testosterone concentration in
older women is associated with greater bone
mineral density, lean body mass, and total
fat mass: the cardiovascular health study. Rariy
CM, Ratcliffe SJ, Weinstein R, Bhasin S,
Blackman MR, Cauley JA, Robbins J, Zmuda JM,
Harris TB, Cappola AR. Division of
Endocrinology, University of Pennsylvania
School of Medicine, Philadelphia,
Pennsylvania 19104, USA. J Clin Endocrinol
Metab. 2011 Apr;96(4):989-96. Epub 2011 Feb
2.
14.Hormonal
Influences Upon Connective Tissue Changes of
Aging, SOBEL
H. and MARMORSTON J. Institute
for Medical Research, Cedars of Lebanon
Hospital, and the Depart-ment of
Biochemistry and Nutrition and the
Department of Medicine, University of
Southern
California, Los Angeles, California,in:
PINCUS G (ed. ) Recent Progress in Hormone
Research, vol. 14. Academic New York 1958.
15. Brain
levels of sex steroid hormones in men and
women during normal aging and in Alzheimer's
disease. Rosario
ER, Chang L, Head EH, Stanczyk FZ, Pike CJ. Davis
School of Gerontology, University of
Southern California, Los Angeles, CA 90089,
USA. Neurobiol
Aging. 2011 Apr;32(4):604-13. Epub 2009 May
9.
16. La
pathologie obstructive congénitale de
l’uretère terminal. G.
Debled : p. 446- 452 ; Acta Urologica
Belgica, 1971, 39, 371-465) See pathology in
: http://www.georgesdebled.org/Pathologie
uretère terminal.pdf
17. High
Court Rejects Pfizer Hormone Therapy Lawsuit
Appeal
Date Published: Wednesday, June 22nd, 2011
The U.S. Supreme Court refused to hear a
Pfizer Inc. unit’s appeal of a $58 million
award in a case
against Premarin and Prempro menopause
drugs.
Three Nevada women who contracted breast
cancer after taking the company’s menopause
drugs
were awarded the amount in a 2007 case.
The rebuff leaves the amount as the largest
to be upheld on appeal in thousands of
hormonereplacement
drug suits. Over six million women took
Prempro and other menopause drugs before a
2002 study pointed out their links to
cancer. At one point Pfizer and his units
faced more than 10,000
claims, according to lawyers for former
users.
The Nevada Supreme Court concluded jurors
properly held Pfizer’s Wyeth unit
responsible for hiding
the breast-cancer
risks of Premarin and Prempro. The original
2007 case resulted in an award totaling
$134.1 million to Arlene Rowatt, Jeraldine
Scofield and Pamela Forrester. The trial
judge later
reduced the verdict to $57.6 million.
Yearly sales of Wyeth’s hormone
replacement
drugs exceeded $2 billion before a 2002
study,
sponsored by the U.S. National Institutes of
Health, suggested that women using the
medicines had a
24 percent higher risk of breast cancer.
Pfizer, the world’s largest drug maker,
acquired Wyeth in 2009 settled a third of
the pending cases
over its Prempro menopause drug. The company
said last month that it set aside $772
million to
resolve claims over the medicine.
18. G. DEBLED.
The menopause disease.
Approaches
to aging control : 19:17-24,October 2015
.jpg){kind=small}
